TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence

EMBO Molecular Medicine

Volumn 6, Issue 10, 2014, Pages 1294-1311

  Ye, Jian ^a   Ma, Chunling ^a,b   Hsueh, Eddy C ^a   Dou, Jie ^a   Mo, Wei ^a   Liu, Shuai ^a   Han, Bing ^a   Huang, Yi ^a   Zhang, Yanping ^a   Varvares, Mark A ^a   Hoft, Daniel F ^a   Peng, Guangyong ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Women and Children's Hospital of Linyi   (China)

Author keywords

Immunosenescence; Regulatory T cells; Toll like receptor; Tumor immunity; Tumor microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIC AMP; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT; POLY G3; SSRNA40; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA; TLR8 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL AGING; CELL SPECIFICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; ENZYME INDUCTION; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR CELL LINE; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CD4+ T LYMPHOCYTE; CELL CULTURE; COCULTURE; DEFICIENCY; DRUG SCREENING; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MCF 7 CELL LINE; METABOLISM; NEOPLASMS; NONOBESE DIABETIC MOUSE; RNA INTERFERENCE; SCID MOUSE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL AGING; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; CYCLIC AMP; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MCF-7 CELLS; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 8; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908111132     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201403918     Document Type: Article

References (55)

1. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA et al (2000) HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 192: 63-75
2. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, Heib V, Becker M, Kubach J, Schmitt S et al (2007) Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 204: 1303-1310
3. Campisi J, d'Adda di Fagagna F (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8: 729-740
4. Chen WH, Kozlovsky BF, Effros RB, Grubeck-Loebenstein B, Edelman R, Sztein MB (2009) Vaccination in the elderly: an immunological perspective. Trends Immunol 30: 351-359
5. Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R, Magdeleinat P, Mami-Chouaib F, Dieu-Nosjean MC, Fridman WH et al (2010) Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 120: 1285-1297
6. Ciubotariu R, Vasilescu R, Ho E, Cinti P, Cancedda C, Poli L, Late M, Liu Z, Berloco P, Cortesini R et al (2001) Detection of T suppressor cells in patients with organ allografts. Hum Immunol 62: 15-20
7. Colombo MP, Piconese S (2007) Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 7: 880-887
8. - T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev 182: 201-206
9. Croci DO, Zacarias Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG (2007) Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 56: 1687-1700
10. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800
11. + T-cell replicative senescence in human aging. Immunol Rev 205: 147-157
12. Gajewski TF (2006) Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 12: 2326s-2330s
13. Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O'Fallon WM, Weyand CM (2001) Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 75: 12182-12187
14. Grader-Beck T, van Puijenbroek AA, Nadler LM, Boussiotis VA (2003) cAMP inhibits both Ras and Rap1 activation in primary human T lymphocytes, but only Ras inhibition correlates with blockade of cell cycle progression. Blood 101: 998-1006
15. Hayflick L (1965) The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 37: 614-636
16. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65: 5009-5014
17. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27: 218-224
18. Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13: 552-559
19. Karin M, Lawrence T, Nizet V (2006) Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124: 823-835
20. + T cells in a dose-dependent fashion. Blood 112: 1175-1183
21. + regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13: 6947-6958
22. Kusmartsev S, Gabrilovich DI (2006) Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 55: 237-245
23. Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, Blazar BR, Chen W (2010) Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 115: 5041-5052
24. - T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 67: 1-12
25. Montes CL, Chapoval AI, Nelson J, Orhue V, Zhang X, Schulze DH, Strome SE, Gastman BR (2008) Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion. Cancer Res 68: 870-879
26. Moreno-Fernandez ME, Rueda CM, Rusie LK, Chougnet CA (2011) Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood 117: 5372-5380
27. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P et al (2006) A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 103: 13132-13137
28. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z et al (2007) Toll-like receptors in tumor immunotherapy. Clin Cancer Res 13: 5280-5289
29. + regulatory T cell function. Science 309: 1380-1384
30. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF (2007) Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27: 334-348
31. Powell DJ Jr, de Vries CR, Allen T, Ahmadzadeh M, Rosenberg SA (2007a) Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. J Immunother 30: 438-447
32. Powell DJ Jr, Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C, White DE, Mavroukakis S, Kreitman RJ, Rosenberg SA et al (2007b) Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 179: 4919-4928
33. Quezada SA, Peggs KS, Curran MA, Allison JP (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116: 1935-1945
34. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR, Campisi J (2009) Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11: 973-979
35. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212: 28-50
36. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915
37. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P (2007) Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 13: 4565-4574
38. Schon M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, Benninghoff B, Slade HB, Gollnick H, Schon MP (2003) Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95: 1138-1149
39. Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A (2008) Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 14: 5947-5952
40. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF (2008) The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13: 859-875
41. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G (2010) Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 184: 1630-1641
42. Tasken K, Stokka AJ (2006) The molecular machinery for cAMP-dependent immunomodulation in T-cells. Biochem Soc Trans 34: 476-479
43. Tsukishiro T, Donnenberg AD, Whiteside TL (2003) Rapid turnover of the CD8(+)CD28(-) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother 52: 599-607
44. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med 9: 1269-1274
45. Vallejo AN (2005) CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev 205: 158-169
46. Van Nguyen T, Puebla-Osorio N, Pang H, Dujka ME, Zhu C (2007) DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model. J Exp Med 204: 1453-1461
47. Vang T, Torgersen KM, Sundvold V, Saxena M, Levy FO, Skalhegg BS, Hansson V, Mustelin T, Tasken K (2001) Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med 193: 497-507
48. Wang RF, Miyahara Y, Wang HY (2008) Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 27: 181-189
49. Wang D, Precopio M, Lan T, Yu D, Tang JX, Kandimalla ER, Agrawal S (2010) Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8. Mol Cancer Ther 9: 1788-1797
50. + regulatory T cells in human ovarian carcinoma. Cancer Res 65: 5020-5026
51. Weng NP, Akbar AN, Goronzy J (2009) CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol 30: 306-312
52. Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904-5912
53. Wolfram RM, Budinsky AC, Brodowicz T, Kubista M, Kostler WJ, Kichler-Lakomy C, Hellan M, Kahlhammer G, Wiltschke C, Zielinski CC (2000) Defective antigen presentation resulting from impaired expression of costimulatory molecules in breast cancer. Int J Cancer 88: 239-244
54. Ye J, Huang X, Hsueh EC, Zhang Q, Ma C, Zhang Y, Varvares MA, Hoft DF, Peng G (2012) Human regulatory T cells induce T-lymphocyte senescence. Blood 120: 2021-2031
55. Ye J, Ma C, Hsueh EC, Eickhoff CS, Zhang Y, Varvares MA, Hoft DF, Peng G (2013) Tumor-derived gammadelta regulatory T Cells suppress innate and adaptive immunity through the Induction of immunosenescence. J Immunol 190: 2403-2414